Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (2)

1

NRG-GY012 : Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

enthalten in: Cancer | 2024

von Rimel, B. | Enserro, D. | Bender, D. | +10

2

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation : Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

enthalten in: Cancer | 2016

von Matulonis, U. | Harter, P. | Gourley, C. | +13

1
[1]